Inflamax Research Inc., today announces the successful completion of patient enrollment in first US Phase II multi-center mEEC™ dose-ranging study with Grass MATAMPL immunotherapy for patients...
(PRWeb March 04, 2016)
Read the full story at http://www.prweb.com/releases/2016/03/prweb13247151.htm